Anemarrhena asphodeloides Bunge ameliorates osteoporosis by suppressing osteoclastogenesis

Lee,Jae Sung; Kim,Mi Hye; Lee,Haesu; Yang,Woong Mο

doi:10.3892/ijmm.2018.3908

Anemarrhena asphodeloides Bunge ameliorates osteoporosis by suppressing osteoclastogenesis

Authors:
- Jae Sung Lee
- Mi Hye Kim
- Haesu Lee
- Woong Mο Yang
View Affiliations

Affiliations: Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Published online on: October 1, 2018 https://doi.org/10.3892/ijmm.2018.3908
Pages: 3613-3621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anemarrhena asphodeloides Bunge has been traditionally used in Korean medicine for its antipyretic, diuretic, sedative, and antitussive effects. In the present study, the effects of an ethanol extract of A. asphodeloides Bunge (AAB) on osteoporosis and its underlying mechanisms on bone remodeling were investigated. Osteoporosis was induced in ICR strain mice by ovariectomy. The mice were divided into four groups: sham, ovariectomized, 17β‑estradiol and 100 mg/kg AAB. The treatment was continued for 4 weeks. Bone mineral density (BMD) and bone mineral content (BMC) were measured using dual‑energy X‑ray absorptiometry. In addition, Raw 264.7 cells were treated in the presence of 0.1, 1 and 10 µg/ml AAB with 100 ng/ml receptor activator of nuclear factor κΒ ligand (RANKL) to induce osteoclast formation and stained with tartrate resistant acid phosphatase. In addition, levels of osteoclast‑related factors were analyzed to investigate the signaling cascades in osteoclasts. The results demonstrated that AAB treatment reversed the decreases of both BMD and BMC in osteoporotic femurs. Additionally, the formation of osteoclasts was significantly suppressed by the AAB treatment in RANKL‑stimulated Raw 264.7 cells. Compared with cells treated with RANKL alone, the AAB‑treated osteoclasts had significantly decreased tumor necrosis factor‑α and interleukin‑6. The protein levels of c‑fos were also decreased in the AAB‑treated osteoclasts. Furthermore, the RANKL‑induced nuclear translocation of nuclear factor‑κB was attenuated in osteoclasts by the AAB treatment compared with cells treated with RANKL alone. Finally, AAB treatment downregulated the phosphorylation of mitogen‑activated protein kinases. The present results demonstrated that AAB exhibited ameliorative effects on osteoporosis by inhibiting osteoclastogenesis, and suggested that AAB may be a potential candidate for the treatment of osteoporosis.

View Figures

View References

1	Consensus development conference: Prophylaxis and treatment of osteoporosis. Am J Med. 90:107–110. 1991. View Article : Google Scholar
2	Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A and Tosteson A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 22:465–475. 2007. View Article : Google Scholar
3	Pietschmann P, Rauner M, Sipos W and Kerschan-Schindl K: Osteoporosis: An age-related and gender-specific disease-a mini-review. Gerontology. 55:3–12. 2009. View Article : Google Scholar
4	El Maataoui A, El Maghraoui A, Biaz A, Elmachtani SI, Dami A, Bouhsain S, Mounach A, Chabraoui L and Ouzzif Z: Relationships between vertebral fractures, sex hormones and vitamin D in Moroccan postmenopausal women: A cross sectional study. BMC Womens Health. 15:412015. View Article : Google Scholar : PubMed/NCBI
5	Karsenty G and Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2:389–406. 2002. View Article : Google Scholar : PubMed/NCBI
6	Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science. 289:1508–1514. 2000. View Article : Google Scholar : PubMed/NCBI
7	Matsumoto Y, Otsuka F, Takano-Narazaki M, Katsuyama T, Nakamura E, Tsukamoto N, Inagaki K, Sada KE and Makino H: Estrogen facilitates osteoblast differentiation by upregulating bone morphogenetic protein-4 signaling. Steroids. 78:513–520. 2013. View Article : Google Scholar : PubMed/NCBI
8	Kelley GA, Kelley KS and Kohrt WM: Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: A meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 13:1772012. View Article : Google Scholar : PubMed/NCBI
9	Hamrick I, Schrager S and Nye AM: Treatment of osteoporosis: Current state of the art. Wien Med Wochenschr. 165:54–64. 2015. View Article : Google Scholar
10	Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, et al: Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the women's health initiative randomized trial. J Bone Miner Res. 21:817–828. 2006. View Article : Google Scholar : PubMed/NCBI
11	Moyer VA; U.S. Preventive Services Task Force: Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 158:691–696. 2013. View Article : Google Scholar : PubMed/NCBI
12	Hansen PJ, Knitschke M, Draenert FG, Irle S and Neff A: Incidence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients taking bisphosphonates for osteoporosis treatment-a grossly underestimated risk? Clin Oral Investig. 17:1829–1837. 2013. View Article : Google Scholar
13	Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rozenberg S and Reginster JY: Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int. 23(Suppl 1): S1–S23. 2012. View Article : Google Scholar : PubMed/NCBI
14	Lee HA, Castro-Aceituno V, Abbai R, Moon SS, Kim YJ, Simu SY and Yang DC: Rhizome of Anemarrhena asphodeloides as mediators of the eco-friendly synthesis of silver and gold spherical, face-centred cubic nanocrystals and its anti-migratory and cytotoxic potential in normal and cancer cell lines. Artif Cells Nanomed Biotechnol. 1–10. 2018.
15	Nian H, Qin LP, Chen WS, Zhang QY, Zheng HC and Wang Y: Protective effect of steroidal saponins from rhizome of Anemarrhena asphodeloides on ovariectomy-induced bone loss in rats. Acta Pharmacol Sin. 27:728–734. 2006. View Article : Google Scholar : PubMed/NCBI
16	Gui Y, Qiu X, Xu Y, Li D and Wang L: Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis via increasing dehydro-epiandrosterone to prevent postmenopausal osteoporosis. Biosci Trends. 9:169–181. 2015. View Article : Google Scholar : PubMed/NCBI
17	He CC, Hui RR, Tezuka Y, Kadota S and Li JX: Osteoprotective effect of extract from Achyranthes bidentata in ovariectomized rats. J Ethnopharmacol. 127:229–234. 2010. View Article : Google Scholar
18	Lee H, Kim MH, Choi YY, Hong J and Yang WM: Effects of Cynanchum wilfordii on osteoporosis with inhibition of bone resorption and induction of bone formation. Mol Med Rep. 17:3758–3762. 2018.
19	Jeon EJ, Lee DH, Kim YJ, Ahn J, Kim MJ, Hwang JT, Hur J, Kim M, Jang YJ, Ha TY, et al: Effects of yuja peel extract and its flavanones on osteopenia in ovariectomized rats and osteoblast differentiation. Mol Nutr Food Res. 60:2587–2601. 2016. View Article : Google Scholar : PubMed/NCBI
20	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
21	Boyce BF, Xiu Y, Li J, Xing L and Yao Z: NF-κB-mediated regulation of osteoclastogenesis. Endocrinol Metabol (Seoul). 30:35–44. 2015. View Article : Google Scholar
22	Kanis JA, Melton LJ III, Christiansen C, Johnston CC and Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 9:1137–1141. 1994. View Article : Google Scholar : PubMed/NCBI
23	Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, et al: Predictive value of BMD for hip and other fractures. J Bone Miner Res. 20:1185–1194. 2005. View Article : Google Scholar : PubMed/NCBI
24	Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC and Cummings SR; OsteoporoticFractures Research Group: BMD at multiple sites and risk of fracture of multiple types: Long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 18:1947–1954. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kim MH, Choi YY, Han JM, Lee HS, Hong SB, Lee SG and Yang WM: Ameliorative effects of Schizandra chinensis on osteoporosis via activation of estrogen receptor (ER)-α/-β. Food Funct. 5:1594–1601. 2014. View Article : Google Scholar : PubMed/NCBI
26	Sims NA and Gooi JH: Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol. 19:444–451. 2008. View Article : Google Scholar : PubMed/NCBI
27	Cao JJ, Wronski TJ, Iwaniec U, Phleger L, Kurimoto P, Boudignon B and Halloran BP: Aging increases stromal/osteo-blastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res. 20:1659–1668. 2005. View Article : Google Scholar : PubMed/NCBI
28	Charles JF and Aliprantis AO: Osteoclasts: More than ‘bone eaters’. Trends Mol Med. 20:449–459. 2014. View Article : Google Scholar : PubMed/NCBI
29	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
30	Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al: Osteoclast differentiation factor is a ligand for osteoprote-gerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602. 1998. View Article : Google Scholar
31	Motiur Rahman M, Takeshita S, Matsuoka K, Kaneko K, Naoe Y, Sakaue-Sawano A, Miyawaki A and Ikeda K: Proliferation-coupled osteoclast differentiation by RANKL: Cell density as a determinant of osteoclast formation. Bone. 81:392–399. 2015. View Article : Google Scholar : PubMed/NCBI
32	Hayman AR: Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 41:218–223. 2008. View Article : Google Scholar : PubMed/NCBI
33	Zou W, Hakim I, Tschoep K, Endres S and Bar-Shavit Z: Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem. 83:70–83. 2001. View Article : Google Scholar : PubMed/NCBI
34	Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F, Araki Y, Akiyama Y, Takeda K and Mimura T: Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol. 66:121–129. 2014. View Article : Google Scholar : PubMed/NCBI
35	Soysa NS and Alles N: NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun. 378:1–5. 2009. View Article : Google Scholar
36	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
37	Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 8:49–62. 2007. View Article : Google Scholar
38	Lee ZH and Kim HH: Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun. 305:211–214. 2003. View Article : Google Scholar : PubMed/NCBI
39	Wagner EF and Eferl R: Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 208:126–140. 2005. View Article : Google Scholar : PubMed/NCBI
40	Wang ZQ, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U and Wagner EF: Bone and haematopoietic defects in mice lacking c-fos. Nature. 360:741–745. 1992. View Article : Google Scholar : PubMed/NCBI